Biopharmconsortium Blog

Expert commentary from Haberman Associates biotechnology and pharmaceutical consulting.

Monthly Archives: September 2011

Update: How the pharmaceutical/biotechnology industry might develop better insulin sensitizers

Tweet  This article is an update of a three-part series on insulin sensitizers for treatment of type 2 diabetes that was published on this blog in August and September of 2010. Summary of our August/September 2010 blog articles on insulin sensitizers In part 1 of the series (posted August 23, 2010), we focused on safety…

Crizotinib (Pfizer’s Xalkori), a multitargeted kinase inhibitor, approved by the FDA for treatment of ALK-driven lung cancer

Tweet  On Aug. 26, 2011, the FDA approved the kinase inhibitor crizotinib (Pfizer’s Xalkori, originally known asĀ  PF-02341066) for treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), in which tumor cells exhibit rearrangements in the anaplastic lymphoma kinase (ALK) gene. These rearrangements of the ALK gene constitute driver mutations that…